1. Tumor-targeting bacteria as immune stimulants – the future of cancer immunotherapy?
- Author
-
Mowday, Alexandra M., van de Laak, Jella M., Fu, Zhe, Henare, Kimiora L., Dubois, Ludwig, Lambin, Philippe, Theys, Jan, and Patterson, Adam V.
- Subjects
- *
TYPE I interferons , *TUMOR-infiltrating immune cells , *TREATMENT effectiveness , *TUMOR microenvironment , *IMMUNE response - Abstract
Cancer immunotherapies have been widely hailed as a breakthrough for cancer treatment in the last decade, epitomized by the unprecedented results observed with checkpoint blockade. Even so, only a minority of patients currently achieve durable remissions. In general, responsive patients appear to have either a high number of tumor neoantigens, a preexisting immune cell infiltrate in the tumor microenvironment, or an 'immune-active' transcriptional profile, determined in part by the presence of a type I interferon gene signature. These observations suggest that the therapeutic efficacy of immunotherapy can be enhanced through strategies that release tumor neoantigens and/or produce a pro-inflammatory tumor microenvironment. In principle, exogenous tumor-targeting bacteria offer a unique solution for improving responsiveness to immunotherapy. This review discusses how tumor-selective bacterial infection can modulate the immunological microenvironment of the tumor and the potential for combination with cancer immunotherapy strategies to further increase therapeutic efficacy. In addition, we provide a perspective on the clinical translation of replicating bacterial therapies, with a focus on the challenges that must be resolved to ensure a successful outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF